ImmunityBio Stock Sinks 21% After FDA Warning on Anktiva Cancer Claims
ImmunityBio shares fell about 21% Tuesday after the FDA warned that ads for its cancer drug Anktiva were false or misleading and violated federal law. The FDA said the materials overstated benefits and promoted unapproved uses. The stock traded near $7.44 late morning. ImmunityBio did not immediately comment.